China Universal Asset Management Company’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$82.1K Sell
7,475
-860
-10% -$6.05K ﹤0.01% 431
2026
Q1
$43.9K Sell
8,335
-5,318
-39% -$29.3K ﹤0.01% 464
2025
Q4
$83K Buy
13,653
+5,421
+66% +$34.7K 0.01% 419
2025
Q3
$42.7K Sell
8,232
-1,214
-13% -$6.74K ﹤0.01% 442
2025
Q2
$54.8K Buy
9,446
+14
+0.1% +$60 0.01% 412
2025
Q1
$26.6K Sell
9,432
-531
-5% -$2.59K ﹤0.01% 449
2024
Q4
$68.5K Buy
+9,963
New +$129K 0.01% 429

Other funds holding SLN

China Universal Asset Management Company's SLN Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Silence Therapeutics (SLN) stake by 10% in Q2 2026, selling an estimated $6.05K and leaving 7,475 shares worth $82.1K. The position accounts for ﹤0.01% of the portfolio, ranked #431.

China Universal Asset Management Company first reported a position in SLN in Q4 2024 and has held it in 7 quarters since. The position peaked at $83K in Q4 2025. 4 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • China Universal Asset Management Company held 7,475 shares of Silence Therapeutics worth $82.1K as of Q2 2026.
  • China Universal Asset Management Company sold 860 Silence Therapeutics shares in Q2 2026, an estimated $6.05K.
  • Silence Therapeutics made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #431 holding.
  • China Universal Asset Management Company first reported a position in Silence Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • China Universal Asset Management Company's Silence Therapeutics position peaked at $83K in Q4 2025.
  • 4 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.